enGene Therapeutics Inc. ENGNW
0.20 USD 0.00 (+0.00%)
Nov 4, 2026, 1:02 PM EST
0.20 Day range 0.20
0.20 52-week range 0.20
- YTD
- 0.00%
- 1 year
- 0.00%
Financial health
Altman Z-Score
1.50 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
A+5 / 5 overall
- DCF 5
- Return on Equity 5
- Return on Assets 5
- Debt / Equity 1
- P/E 4
- P/B 5
Valuation
P/E -3.1×
FY 2020 5y median -6.1× FY 2025
P/S 0.0×
FY 2020 5y median 0.0× FY 2025
P/B 2.2×
FY 2020 5y median 2.5× FY 2025
P/FCF -3.7×
FY 2020 5y median -17.8× FY 2025
EV/EBITDA -3.1×
FY 2020 5y median -4.7× FY 2025
EV/Sales 0.0×
FY 2020 5y median 0.0× FY 2025
FCF Yield -27.3%
FY 2020 5y median -5.6% FY 2025
Profitability
Gross Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2020 5y median 0.0% FY 2025
ROE -69.9%
FY 2020 5y median -20.2% FY 2025
ROIC -61.7%
FY 2020 5y median -20.9% FY 2025
ROA -53.0%
FY 2020 5y median -18.5% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2020 FY 2025
Operating Income -97.7%
FY 2020 FY 2025
EPS (diluted) -56.8%
FY 2020 FY 2025
Free Cash Flow -104.7%
FY 2020 FY 2025
Financial Health
Current Ratio 6.3×
FY 2020 5y median 6.3× FY 2025
Quick Ratio 6.3×
FY 2020 5y median 6.3× FY 2025
Debt / Equity 0.2×
FY 2020 5y median 0.1× FY 2025
Net Debt / EBITDA 0.2×
FY 2020 5y median 0.2× FY 2025
Interest Coverage -41.1×
FY 2020 5y median -13.7× FY 2025
Dividends
Dividend Yield 0.0%
FY 2020 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2020 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-10-31